NeuroSense Therapeutics (NRSN) Competitors $1.22 0.00 (-0.33%) As of 09:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRSN vs. INKT, JATT, NRXP, DTIL, ANL, ALGS, GNTA, ACRV, IMMX, and DRRXShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include MiNK Therapeutics (INKT), JATT Acquisition (JATT), NRx Pharmaceuticals (NRXP), Precision BioSciences (DTIL), Adlai Nortye (ANL), Aligos Therapeutics (ALGS), Genenta Science (GNTA), Acrivon Therapeutics (ACRV), Immix Biopharma (IMMX), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. NeuroSense Therapeutics vs. Its Competitors MiNK Therapeutics JATT Acquisition NRx Pharmaceuticals Precision BioSciences Adlai Nortye Aligos Therapeutics Genenta Science Acrivon Therapeutics Immix Biopharma DURECT NeuroSense Therapeutics (NASDAQ:NRSN) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Do institutionals & insiders believe in NRSN or INKT? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor NRSN or INKT? In the previous week, NeuroSense Therapeutics had 7 more articles in the media than MiNK Therapeutics. MarketBeat recorded 9 mentions for NeuroSense Therapeutics and 2 mentions for MiNK Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.59 beat MiNK Therapeutics' score of 0.64 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MiNK Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, NRSN or INKT? NeuroSense Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Do analysts rate NRSN or INKT? NeuroSense Therapeutics currently has a consensus target price of $14.00, indicating a potential upside of 1,051.32%. MiNK Therapeutics has a consensus target price of $37.50, indicating a potential upside of 166.88%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.67MiNK Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.33 Is NRSN or INKT more profitable? Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A N/A MiNK Therapeutics N/A N/A -227.24% Which has better valuation and earnings, NRSN or INKT? MiNK Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-2.25MiNK TherapeuticsN/AN/A-$9.51M-$2.88-4.88 SummaryNeuroSense Therapeutics beats MiNK Therapeutics on 10 of the 13 factors compared between the two stocks. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.95M$3.41B$6.08B$10.55BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-2.2723.0784.6627.19Price / SalesN/A486.15608.04132.91Price / CashN/A46.9737.8662.13Price / Book6.4010.5012.386.65Net Income-$10.21M-$52.47M$3.32B$276.79M7 Day Performance2.18%2.90%2.25%1.75%1 Month Performance3.05%15.36%9.63%5.15%1 Year Performance10.55%14.29%73.84%36.96% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics3.3553 of 5 stars$1.22-0.3%$14.00+1,051.3%+24.6%$16.95MN/A-2.2710News CoverageAnalyst UpgradeShort Interest ↓Analyst RevisionINKTMiNK Therapeutics2.324 of 5 stars$15.19+1.1%$37.50+146.9%+109.3%$67.91MN/A-5.2730JATTJATT AcquisitionN/A$3.93-4.1%N/A-10.8%$67.79MN/A0.003High Trading VolumeNRXPNRx Pharmaceuticals3.0174 of 5 stars$3.35+2.4%$34.50+929.9%+147.2%$64.78MN/A-1.502Analyst ForecastDTILPrecision BioSciences3.908 of 5 stars$5.67+4.2%$47.00+728.9%-26.3%$64.12M$68.70M-0.64200ANLAdlai Nortye1.2626 of 5 stars$1.76+1.7%$9.00+411.7%-16.9%$63.84M$5M0.00127Short Interest ↑ALGSAligos Therapeutics3.8946 of 5 stars$10.22+1.5%$50.00+389.2%+42.4%$61.94M$3.94M-0.5290News CoverageGNTAGenenta Science0.9705 of 5 stars$3.22-2.4%N/A-43.2%$60.36MN/A0.007ACRVAcrivon Therapeutics3.2495 of 5 stars$1.91flat$15.00+685.3%-75.9%$60.08MN/A-0.8558Positive NewsIMMXImmix Biopharma3.3308 of 5 stars$2.24+8.7%$8.00+257.1%+87.5%$59.40MN/A-2.919High Trading VolumeDRRXDURECTN/A$1.91flatN/AN/A$59.31M$1.66M-19.1080 Related Companies and Tools Related Companies INKT Competitors JATT Competitors NRXP Competitors DTIL Competitors ANL Competitors ALGS Competitors GNTA Competitors ACRV Competitors IMMX Competitors DRRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRSN) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
